Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740609 · ClinicalTrials.gov registry record · Phase 1
A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT01740609 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 80 participants.
The verdict
NCT01740609, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses PF-06342674.
Interventions
- DRUG Placebo
- BIOLOGICAL PF-06342674 Dose A
- BIOLOGICAL PF-06342674 Dose B
- BIOLOGICAL PF-06342674 Dose C
- BIOLOGICAL PF-06342674 Dose D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01740609
The ClinicalTrials.gov registry entry for NCT01740609 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01740609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01740609 about?
NCT01740609 is a clinical study titled "A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses PF-06342674.
What is the current status of trial NCT01740609?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2012-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01740609?
The interventions under investigation include: Placebo (DRUG), PF-06342674 Dose A (BIOLOGICAL), PF-06342674 Dose B (BIOLOGICAL), PF-06342674 Dose C (BIOLOGICAL), PF-06342674 Dose D (BIOLOGICAL).
Who is sponsoring clinical trial NCT01740609?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.